1,572 Labcorp Holdings Inc. $LH Shares Sold by Carmel Capital Partners LLC

Posted by Geri Gentry on Nov 7th, 2026

Carmel Capital Partners LLC decreased its holdings in shares of Labcorp Holdings Inc. (NYSE:LH – Free Report) by 14.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,229 shares of the medical research company’s stock after selling 1,572 shares during the period. Labcorp makes up about 1.0% of Carmel Capital Partners LLC’s portfolio, making the stock its 24th largest position. Carmel Capital Partners LLC’s holdings in Labcorp were worth $2,844,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Allspring Global Investments Holdings LLC raised its holdings in shares of Labcorp by 1.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,226,446 shares of the medical research company’s stock worth $607,241,000 after acquiring an additional 22,170 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Labcorp by 2.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,332,775 shares of the medical research company’s stock valued at $355,569,000 after purchasing an additional 28,584 shares during the last quarter. Royal Bank of Canada increased its holdings in Labcorp by 19.4% during the 1st quarter. Royal Bank of Canada now owns 820,442 shares of the medical research company’s stock worth $218,901,000 after purchasing an additional 133,549 shares in the last quarter. Diamond Hill Capital Management LLC Investment Advisor bought a new stake in Labcorp during the 2nd quarter worth approximately $168,222,000. Finally, Bessemer Group Inc. raised its stake in shares of Labcorp by 47.3% in the first quarter. Bessemer Group Inc. now owns 579,036 shares of the medical research company’s stock worth $154,493,000 after purchasing an additional 185,847 shares during the last quarter. 95.94% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Bryan T. Vaughn sold 306 shares of the stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $353.70, for a total transaction of $108,232.20. Following the sale, the executive vice president owned 6,845 shares of the company’s stock, valued at approximately $2,421,076.50. This represents a 4.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam H. Schechter sold 4,669 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total value of $1,495,807.53. Following the completion of the transaction, the chief executive officer owned 102,565 shares of the company’s stock, valued at approximately $32,858,749.05. This represents a 4.35% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 9,053 shares of company stock valued at $2,947,495 over the last three months. Insiders own 0.84% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on LH. Piper Sandler upped their price target on Labcorp from $300.00 to $309.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $355.00 target price on shares of Labcorp in a research note on Thursday, October 29th. Mizuho set a $355.00 target price on shares of Labcorp in a report on Monday, August 10th. Weiss Ratings upgraded shares of Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a report on Wednesday, October 21st. Finally, Truist Financial upped their price objective on shares of Labcorp from $365.00 to $395.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Labcorp presently has a consensus rating of “Moderate Buy” and a consensus target price of $369.08.

Get Our Latest Report on LH

Labcorp Stock Performance

Shares of LH stock traded up $3.60 on Friday, hitting $366.90. 610,112 shares of the stock were exchanged, compared to its average volume of 761,004. The firm’s 50 day moving average is $325.66 and its two-hundred day moving average is $290.01. Labcorp Holdings Inc. has a one year low of $244.52 and a one year high of $373.34. The firm has a market capitalization of $29.79 billion, a PE ratio of 30.10, a P/E/G ratio of 2.01 and a beta of 0.86. The company has a current ratio of 1.41, a quick ratio of 1.22 and a debt-to-equity ratio of 0.60.

Labcorp (NYSE:LH – Get Free Report) last issued its earnings results on Wednesday, October 28th. The medical research company reported $4.78 earnings per share for the quarter, topping analysts’ consensus estimates of $4.64 by $0.14. Labcorp had a net margin of 6.88% and a return on equity of 17.13%. The firm had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the business earned $4.18 earnings per share. The company’s quarterly revenue was up 6.9% on a year-over-year basis. Sell-side analysts expect that Labcorp Holdings Inc. will post 18.51 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Tuesday, November 24th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $2.88 dividend on an annualized basis and a yield of 0.8%. Labcorp’s payout ratio is presently 23.63%.

Labcorp Company Profile

(Free Report)

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences company that provides diagnostic testing and services to patients, physicians, hospitals, employers and other health care organizations. Its offerings include routine and specialty laboratory tests, anatomic pathology and genetic testing.

The company also supports pharmaceutical and biotechnology companies with laboratory services for drug development and clinical trials, including testing and analysis used in research and clinical studies.

Labcorp was formed in 1995 through the combination of National Health Laboratories and Roche Biomedical Laboratories.